Safety and efficacy of first-line tepotinib (MSC2156119J)in a phase Ⅰb trial in Asian patients with

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户：yanlian2008

【摘要】

：

Objective: The overall prognosis of advanced hepatocellular cancer (HCC) remains poor, with c-Met abnormalities associated with a particularly poor prognosis.The highly selective c-Met inhibitor tepot

【作者】

：

Shukui Qin Ho yeong Lim Baek-yeol Ryoo Cindy Li Huiling Xiong Christian Ihling Ann-lii Cheng

【机构】

：

Medical Oncology Department, Nanjing Bayi Hospital, Nanjing, China

【出处】

：

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会

【发表日期】

：

2015年4期

【关键词】

：

hepatocellular cancer

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

其他文献

High NK Cell Dose Predicts Improved Survival and ADCC Effect of Trastuzumab in HER-2 Positive Metast

Objective: Trastuzumab has been shown to medicate antibody dependent cell mediated cytotoxicity (ADCC) and inhibit HER-2.Associated Natural Killer (NK) cell with ADCC effect in metastatic breast cance

会议

metastatic breast cancer trastuzumab natural kille

ER-alpha promoter methylation is a specific biomarker for outcome prediction of cisplatin resistant

Objective: An increasing number of studies have suggested that the link between ERα methylation and triple-negative breast cancer (TNBC).We previously found the ERα methylation status in basal-like br

会议

TNBC ERα methylationcisplatin resistant

Feasibility Study of fixed overlap field IMRT approach for mid and/or distal esophageal cancer with

Objective: Proposed a new IMRT treatment planning technique with the potential of reducing low dose region of the lungs in esophageal cancer patients treated with defmitive chemoradiotherapy.

会议

esophageal cancerintensity modulated radiotherapy

即刻淋巴静脉吻合预防上肢淋巴水肿的应用探索

目的：对即刻淋巴静脉吻合预防上肢淋巴水肿进行初步临床应用，探索术中在显微镜近红外光成像系统下应用吲哚菁绿淋巴造影，研究其淋巴管显像情况，协助淋巴管断端定位。方法：对2015年4月至6月收治的3例乳腺癌需腋窝淋巴结清扫的患者进行即刻淋巴静脉吻合。

会议

即刻淋巴静脉吻合淋巴水肿预防显微镜近红外光成像系统下吲哚菁绿淋巴造影

Laparoscopic versus open abdominal peritoneal resection for rectal cancer: a case-matched study of p

Objective: The aim of the study is to evaluate the safety and feasibility of laparoscopic abdominal peritoneal resection (LAPR) for rectal cancer compared with conventional open abdominal peritoneal r

会议

Laparoscopicabdominal peritoneal resectionrectal

Evaluation of the frequency of MET Expression and Amplification in Chinese Hepatocellular Carcinoma

Objective: MET is a potential therapeutic target in hepatocellular carcinoma (HCC).This study evaluated MET expression and amplification in Chinese HCC patients and investigated the relationship with

会议

METHCC

Clinicopathological features and the prognostic factors of colorectal neuroendocrine neoplasms (NENs

Objective: The World Health Organization classifies neuroendocrine neoplasms of the colon and rectum together as a single entity, but there is significant difference observed between them.

会议

Colorectal neuroendocrine neoplasmsPrognostic fac

The influence of marital status on stage at diagnosis and survival of patients with colorectal neuro

Objective: Research indicates an association between marital status and health but this link hasnt been thoroughly explored.Our goal was to examine the association of marital status on the survival ou

会议

colorectal neuroendocrine neoplasmsmarital statusprognostic analysis

The result of Phase 1b and phase 2 study of selective VEGFR inhibitor fruquintinib as 3+ line therap

Objective: Fruquintinib is a novel oral small molecule compound selectively inhibits vascular endothelial growth factor receptors (VEGFR)1, 2, and 3 with potent inhibitory effects on multiple human tu

会议

FruquintinibmCRCPFS

Prospective Randomized Phase Ⅱ Study of FOLFIRI versus FOLFOX7 in Advanced Gastric Adenocarcinoma: a

Objective: The purpose was to compare folinic acid, 5-fluorouracil (5-FU), and irinotecan (mFOLFIRI;arm A) with folinic acid, 5-FU, and oxaliplatin (mFOLFOX7;arm B) as first-line treatments in patient

会议

Advanced Gastric AdenocarcinomaFOLFIRIFOLFOX7

Safety and efficacy of first-line tepotinib (MSC2156119J)in a phase Ⅰb trial in Asian patients with

与本文相关的学术论文